Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.
about
Receptor for advanced glycation end products and its involvement in inflammatory diseasesInteraction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42How hyperglycemia promotes atherosclerosis: molecular mechanisms.Markers of oxidative stress and aging in Duchene muscular dystrophy patients and the possible ameliorating effect of He:Ne laser.RAGE signaling in inflammation and arterial aging.Development of capture assays for different modifications of human low-density lipoprotein.The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculaturePathophysiological relationships between periodontitis and systemic disease: recent concepts involving serum lipids.Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patientsThe multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.Periodontitis and diabetes interrelationships: role of inflammation.S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and releaseSurvey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.Central role of RAGE-dependent neointimal expansion in arterial restenosis.Diabetic complications and dysregulated innate immunity.Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteinsImmunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets.Pathophysiology and Medical Treatment of Carotid Artery Stenosis.Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.RAGE and its ligands: a lasting memory in diabetic complications?Effects of bone marrow MSCs transfected with sRAGE on the intervention of HMGB1 induced immuno-inflammatory reactionComplementary roles for scavenger receptor A and CD36 of human monocyte-derived macrophages in adhesion to surfaces coated with oxidized low-density lipoproteins and in secretion of H2O2.Advanced glycation end products: Key players in skin aging?RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory responseThe receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationVascular effects of advanced glycation endproducts: Clinical effects and molecular mechanismsIdentification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer.The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes.Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?The emerging role of the receptor for advanced glycation end products on innate immunity.Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diaLeukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyl
P2860
Q21285070-CC6182F1-F35E-4013-AD1F-C7D041448EECQ24323192-766E2DE4-9269-4DB6-9C7C-597F05D1AFFBQ24795988-508307DF-97DC-4655-94AD-F19F49623E35Q33301531-C84BADF0-B0C6-4895-996D-34F4057DA44BQ33346824-F568A508-3835-4BAF-98E5-B09ED1993BC6Q33593614-88F1AB73-29D5-42FA-9848-D6F80D79FE0CQ33822512-B1521F9A-30F6-475C-B586-A76973C4E0E5Q34023096-40743C1E-7A1B-4769-88D2-11C7F27875E5Q34362687-3D583425-F585-4877-8254-43022D12271DQ34387881-049089AA-A820-4574-A9FF-CD6AB2D96AF5Q34557654-16EC9152-E90C-4076-B227-6623FFBFFEBEQ34606206-6004581F-61DD-4493-A811-05B2A0C2AC1DQ34728855-920AC75E-20AF-4C67-98A8-8FB9E6281E9BQ34890522-A9B10322-B4AE-436A-8A47-6BA238B4380DQ35087841-7DF2CAC5-C62E-45B0-A6AB-455CF0F7C553Q35661794-FBABED27-0ED4-4703-A808-E980BAA9323FQ35664175-CBCCBF51-9516-4766-857C-F4FEBA557D31Q35748423-A961B7C1-9688-4535-8C5D-7A44C3854D9AQ35798371-97BD0220-629A-4A3E-9285-7B2F6C47B809Q35865399-1B749206-0D0E-4A57-824E-DFB6FC4BEBA9Q36065338-A682DA38-1219-4349-8303-F9D41C494F28Q36069797-7D2C8517-96EA-46BF-9F63-1F21197C2985Q36320548-09505F68-8444-4356-A534-9331095785C8Q36375004-69EE3AA8-5A64-4EFC-AEDC-77E3B40A8D48Q36401387-202A4D08-32CA-400F-A596-0575359C00E1Q36643573-AAB8B091-24A9-47A0-B4EC-2BB6066333E0Q36969021-23237D65-D123-4B75-B8D2-6E9E55254011Q37384331-BF14CC48-31C6-4718-9E07-44FAC3F95797Q37412673-2CA747E6-074A-44E4-B82F-C2F1C41E2A38Q37424029-F58974FD-B5F2-4D4A-9649-2C611EBC05A5Q37636453-02457B50-C62B-47B8-BE5E-A4553507DBFDQ37692742-73CFB94D-295E-442B-90D7-B89C5E0FC876Q37825897-C0AE584D-88A5-444D-86FE-6535626A1BCCQ38023062-B229F041-FFA4-49E6-9D5B-3C9D5360196EQ38150990-3C7E7B5B-94B9-42FB-BD87-38721154E42AQ38165257-F1964F41-437D-43B3-83C9-E3C3EAB1F4E8Q38292287-06294F13-41C3-441F-A213-0D15A60715E6Q39466560-D613B6A5-DF2A-4047-ADB2-435B1EEA91E7Q39759463-311BED9C-18C5-443B-B20D-F19E58D31846Q39770000-91C4CBE7-E4F9-4A70-B5DC-62A6A86FEE87
P2860
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Regulation of human mononuclea ...... vanced glycation end products.
@en
type
label
Regulation of human mononuclea ...... vanced glycation end products.
@en
prefLabel
Regulation of human mononuclea ...... vanced glycation end products.
@en
P2093
P2860
P356
P1476
Regulation of human mononuclea ...... vanced glycation end products.
@en
P2093
P2860
P304
P356
10.1172/JCI116442
P407
P577
1993-05-01T00:00:00Z